OKYO Pharma (OKYO) Accounts Payables (2021 - 2026)
OKYO Pharma (OKYO) posted quarterly Accounts Payables of $8.6 million for Q1 2026, up 3.27% year-over-year from $8.4 million in Q1 2025, and up 13.11% quarter-over-quarter from $7.6 million in Q3 2025.
OKYO Pharma (OKYO) Accounts Payables (2021 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Accounts Payables for 6 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 3.27% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (up 3.27% YoY), while the FY2026 annual figure was $8.6 million, up 3.27% from the prior year.
- Accounts Payables climbed to $8.6 million in Q1 2026 per OKYO's latest filing, from $7.6 million in the prior quarter.
- Across five years, Accounts Payables topped out at $9.6 million in Q3 2024 and bottomed at $1.3 million in Q1 2022.
- Historically, Accounts Payables has averaged $6.5 million across 5 years, with a median of $7.4 million in 2024.
- Annual changes were most pronounced in 2022 — Accounts Payables decreased 21.93% — and 2023, when it soared 226.37%.
- OKYO Pharma's Accounts Payables stood at $1.3 million in 2022, then jumped by 315.15% to $5.4 million in 2023, then soared by 77.17% to $9.6 million in 2024, then retreated by 20.48% to $7.6 million in 2025, then grew by 13.11% to $8.6 million in 2026.
- Business Quant data shows OKYO's Accounts Payables at $8.6 million in Q1 2026, $7.6 million in Q3 2025, and $8.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | OKYO Pharma | 1.52 Bn | 1.52 Bn | - | 8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.64 Mn |
| Sep 30, 2025 | 7.64 Mn |
| Mar 31, 2025 | 8.37 Mn |
| Sep 30, 2024 | 9.61 Mn |
| Mar 31, 2024 | 7.06 Mn |
| Sep 30, 2023 | 5.42 Mn |
| Mar 31, 2023 | 4.26 Mn |
| Mar 31, 2022 | 1.31 Mn |
| Mar 31, 2021 | 1.67 Mn |